UNICA IRIS Institutional Research Information System

SCARTOZZI, MARIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 233.769
NA - Nord America 18.682
AS - Asia 3.229
SA - Sud America 45
AF - Africa 35
OC - Oceania 20
Continente sconosciuto - Info sul continente non disponibili 18
Totale 255.798
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 228.799
US - Stati Uniti d'America 18.566
CN - Cina 1.863
UA - Ucraina 1.715
SE - Svezia 1.138
DE - Germania 774
SG - Singapore 754
FI - Finlandia 521
GB - Regno Unito 375
TR - Turchia 181
VN - Vietnam 169
FR - Francia 125
CA - Canada 100
NL - Olanda 80
IN - India 78
KR - Corea 71
BE - Belgio 47
RU - Federazione Russa 42
BR - Brasile 29
IE - Irlanda 29
IR - Iran 27
JP - Giappone 26
HK - Hong Kong 20
EU - Europa 18
AT - Austria 16
AU - Australia 16
ES - Italia 16
PL - Polonia 15
RO - Romania 12
CZ - Repubblica Ceca 9
HR - Croazia 9
MX - Messico 9
IS - Islanda 8
CO - Colombia 7
CH - Svizzera 6
ID - Indonesia 6
JE - Jersey 6
TZ - Tanzania 6
ZA - Sudafrica 6
CI - Costa d'Avorio 5
SK - Slovacchia (Repubblica Slovacca) 5
BG - Bulgaria 4
CL - Cile 4
GR - Grecia 4
IL - Israele 4
MU - Mauritius 4
MY - Malesia 4
NZ - Nuova Zelanda 4
PH - Filippine 4
PT - Portogallo 4
TH - Thailandia 4
BD - Bangladesh 3
BJ - Benin 3
BZ - Belize 3
EG - Egitto 3
IQ - Iraq 3
JO - Giordania 3
PE - Perù 3
SC - Seychelles 3
TW - Taiwan 3
BY - Bielorussia 2
DK - Danimarca 2
DZ - Algeria 2
NO - Norvegia 2
PA - Panama 2
RS - Serbia 2
AE - Emirati Arabi Uniti 1
AF - Afghanistan, Repubblica islamica di 1
AR - Argentina 1
BN - Brunei Darussalam 1
BS - Bahamas 1
EC - Ecuador 1
ET - Etiopia 1
GH - Ghana 1
HU - Ungheria 1
KZ - Kazakistan 1
LV - Lettonia 1
MA - Marocco 1
MO - Macao, regione amministrativa speciale della Cina 1
PK - Pakistan 1
TT - Trinidad e Tobago 1
Totale 255.798
Salva come PNG Salva come JPEG
Città #
Cagliari 219.143
Uta 8.464
Fairfield 2.638
Woodbridge 1.936
Chandler 1.562
Boardman 1.431
Houston 1.353
Ashburn 1.263
Seattle 1.023
Wilmington 999
Cambridge 903
Jacksonville 887
Ann Arbor 830
Nyköping 830
Dearborn 391
Singapore 388
Nanjing 314
Helsinki 257
Beijing 202
Santa Clara 182
Boston 178
Dong Ket 166
Shanghai 156
Istanbul 153
San Diego 149
New York 137
Guangzhou 116
Shenyang 108
Milan 104
Rome 97
Krefeld 95
Nanchang 90
Hebei 85
Verona 82
Jiaxing 79
Los Angeles 75
Toronto 73
Changsha 64
Seoul 58
Tianjin 58
London 54
Norwalk 51
Bad Bellingen 49
Mountain View 47
Pune 47
Washington 45
Zhengzhou 44
Brussels 42
Orange 41
Redwood City 40
Sassari 39
Jinan 38
Phoenix 34
Hefei 32
Amsterdam 31
Wuhan 31
Munich 30
Hangzhou 26
Ningbo 26
Kunming 25
Shenzhen 25
Chicago 22
Dublin 20
Redmond 20
Atlanta 17
Falls Church 17
Saint Petersburg 17
Borås 15
Vienna 15
Cedar Knolls 14
Leawood 14
Paris 14
Hong Kong 13
Indiana 13
Taizhou 13
Kilburn 12
Montreal 12
San Francisco 12
Simaxis 12
Berlin 11
Detroit 11
Edinburgh 11
Naples 11
Wuxi 11
Ankara 10
Fuzhou 10
Hounslow 10
San Mateo 10
West Lafayette 10
Augusta 9
Bari 9
Chongqing 9
Islington 9
Zagreb 9
Miami 8
Reykjavik 8
Rio de Janeiro 8
Rockville 8
Torino 8
Chiswick 7
Totale 248.385
Salva come PNG Salva come JPEG
Nome #
Thyroid dysfunction and ultrasonography features in patients with metastatic colorectal cancer treated with Regorafenib: preliminary results from a single prospective cohort study. 4.760
Pathophysiology of cardiotoxicity induced by nonanthracycline chemotherapy 4.059
Timing of the negative effects of trastuzumab on cardiac mechanics after anthracycline chemotherapy 3.449
Aspirin as a neoadjuvant agent during preoperative chemoradiation for rectal cancer 3.217
Clustered protocadherins methylation alterations in cancer 3.172
BRAF-mutant colorectal cancer, a different breed evolving 3.131
The Role of Aspirin as Antitumoral Agent for Heavily Pretreated Patients With Metastatic Colorectal Cancer Receiving Capecitabine Monotherapy 3.049
null 3.029
Aspirin and cancer risk 2.991
Systemic therapy for the treatment of endometrial cancer 2.955
Regorafenib-induced hypothyroidism and cancer-related fatigue: is there a potential link? 2.858
Thyroid dysfunction and ultrasonography features in patients with metastatic colorectal cancer treated with Regorafenib. Results from a single centre prospective cohort study. 2.814
Molecular-biology-driven treatment for metastatic colorectal cancer 2.609
Acetylsalicylic acid as a neo-adjuvant agent during preoperative chemoradiation for rectal cancer 2.575
Breast MRI: Clinical Indications, Recommendations, and Future Applications in Breast Cancer Diagnosis 2.539
HOXD8 hypermethylation as a fully sensitive and specific biomarker for biliary tract cancer detectable in tissue and bile samples 2.536
Thyroid dysfunction in disguise and treatment-related fatigue in the spotlight among metastatic colorectal cancer patients receiving regorafenib: Implications for clinical management. 2.496
CREAM study: Clinical correlation between ipilimumab-Related colitis And intestinal Microbiote in metastatic melanoma patients 2.449
Aggressive differentiated thyroid cancer with multiple metastases and NRAS and TERT promoter mutations: A case report 2.355
Alterazioni tiroidee funzionali e morfologiche in pazienti affetti da carcinoma del colon-retto metastatico in trattamento con Regorafenib. Risultati di uno studio prospettico. 2.313
Colorectal cancer early detection in stool samples tracing CPG islands methylation alterations affecting gene expression 2.210
Off-target effects and clinical outcome in metastatic colorectal cancer patients receiving regorafenib: The TRIBUTE analysis 2.207
Alterazioni tiroidee funzionali e morfologiche in pazienti affetti da carcinoma del colon-retto metastatico in trattamento con Regorafenib. 2.207
HYPOTHYROIDISM AND THYROID AUTOIMMUNITY AS A PROGNOSTIC BIOMARKER OF BETTER RESPONSE IN METASTATIC CANCER LONG SURVIVORS TREATED WITH SUNITINIB 2.142
Second-line angiogenesis inhibition in metastatic colorectal cancer patients: Straightforward or overcrowded? 2.129
Radiological evaluation of response to immunotherapy in brain tumors: Where are we now and where are we going? 2.117
Gold nanoparticles: A new golden Era in oncology? 2.103
Immunotherapy associated pulmonary toxicity: Biology behind clinical and radiological features 2.075
Health related quality of life in patients with onco-hematological diseases 2.068
The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab 2.056
The abscopal effect in the era of cancer immunotherapy: a spontaneous synergism boosting anti-tumor immunity? 2.042
Prognostic Value of Thyroid Hormone Ratios in Patients With Advanced Metastatic Colorectal Cancer Treated With Regorafenib: The TOREADOR Study 2.012
Ipotiroidismo e autoimmunità tiroidea in pazienti affetti da carcinoma renale metastatico trattati con sunitinib con un follow-up di 30 mesi. 1.996
Microenvironmental M1 tumor-associated macrophage polarization influences cancer-related anemia in advanced ovarian cancer: Key role of interleukin-6 1.934
Impact of Baseline Characteristics on the Overall Survival of HCC Patients Treated with Sorafenib: Ten Years of Experience 1.922
The immune revolution in gastrointestinal tumours: leading the way or just following? 1.850
Hypothyroidism and thyroid autoimmunity in metastatic renal cell carcinoma patients treated with sunitinib: 2 years follow-up of long survivors from a single centre experience. 1.845
From central to sentral (Serum angiogenesis central): Circulating predictive biomarkers to anti-VEGFR therapy 1.822
A validated prognostic classifier for V600EBRAF-mutated metastatic colorectal cancer: the 'BRAF BeCool' study 1.767
Next generation sequencing driven successful combined treatment with laparoscopic surgery and immunotherapy for relapsed stage IVB cervical and synchronous stage IV lung cancer 1.678
Critical features and challenges associated with imaging in patients undergoing cancer immunotherapy 1.581
Profile of lenvatinib in the treatment of hepatocellular carcinoma: design, development, potential place in therapy and network meta-analysis of hepatitis B and hepatitis C in all Phase III trials 1.510
New therapeutic targets in pancreatic cancer 1.504
The Quality of Life of People with Solid Cancer is Less Worse than Other Diseases with better Prognosis, Except in the Presence of Depression 1.492
Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study 1.491
Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients 1.469
Why precision medicine should be applied across the continuum of care for metastatic colorectal cancer patients? 1.401
Immune inflammation indicators in anal cancer patients treated with concurrent chemoradiation: Training and validation cohort with online calculator (ARC: Anal Cancer Response Classifier) 1.395
Contemporary best practice in the management of urothelial carcinomas of the renal pelvis and ureter 1.363
Tumor infiltrating lymphocytes in gastrointestinal tumors: Controversies and future clinical implications 1.340
ANGPT2 and NOS3 Polymorphisms and Clinical Outcome in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib 1.316
Mismatch repair deficiency may affect clinical outcome through immune response activation in metastatic gastric cancer patients receiving first-line chemotherapy 1.301
Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations 1.283
The distinctive molecular, pathological and clinical characteristics of BRAF-mutant colorectal tumors 1.259
Association of NOS3 and ANGPT2 Gene Polymorphisms with Survival in Patients with Hepatocellular Carcinoma Receiving Sorafenib: Results of the Multicenter Prospective INNOVATE Study 1.244
Hepatocellular carcinoma and microbiota: Implications for clinical management and treatment 1.222
Second-line chemotherapy for advanced pancreatic cancer: Which is the best option? 1.216
First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: final results of the GISCAD (Italian Group for the Study of Digestive Tract Cancers) CENTRAL (ColorEctalavastiNTRiAlLdh) trial 1.210
Immunotherapy for colorectal cancer: where are we heading? 1.187
Cancer immunotherapy-associated hypophysitis 1.152
Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma 1.137
Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers? 1.132
Retreatment With Anti-EGFR Antibodies in Metastatic Colorectal Cancer Patients: A Multi-institutional Analysis 1.126
The prognostic impact of primary tumour location in patients with stage II and stage III colon cancer receiving adjuvant therapy. A GISCAD analysis from three large randomised trials 1.123
The prognostic role of hemoglobin levels in patients undergoing concurrent chemo-radiation for anal cancer 1.122
Early onset of hypertension and serum electrolyte changes as potential predictive factors of activity in advanced hcc patients treated with sorafenib: results from a retrospective analysis of the HCC-AVR group 1.098
Molecular-driven treatment for biliary tract cancer: the promising turning point 1.085
null 1.080
Interplay Between SIRT-3, Metabolism and Its Tumor Suppressor Role in Hepatocellular Carcinoma 1.048
How to improve metastatic pancreatic ductal adenocarcinoma patients' selection: Between clinical trials and the real-world 1.043
eNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: Final results of the ePHAS study 1.028
Anti-EGFR Therapy in Metastatic Small Bowel Adenocarcinoma: Myth or Reality? 1.021
Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An Innovate study protocol 993
Lactate dehydrogenase in hepatocellular carcinoma: something old, something new 958
Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study 958
The role of fetal programming in human carcinogenesis - May the Barker hypothesis explain interindividual variability in susceptibility to cancer insurgence and progression? 934
Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale 933
Antiangiogenic agents after first line and sorafenib plus chemoembolization: A systematic review 927
Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: A retrospective study 902
Colorectal cancer promoter methylation alteration affects the expression of glutamate ionotropic receptor AMPA type subunit 4 alternative isoforms potentially relevant in colon tissue 900
Thyroid hormones ratio is a major prognostic marker in advanced metastatic colorectal cancer: Results from the phase III randomised CORRECT trial 882
Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma 877
Systemic chemotherapy for advanced rare pancreatic histotype tumors: A retrospective multicenter analysis 877
The association between Major Depressive Disorder and premature death risk in hematologic and solid cancer: a longitudinal cohort study 877
FOLFOX or CAPOX in stage II to III colon cancer: Efficacy results of the italian three or six colon adjuvant trial 871
STUDY OF VALIDATION OF ANGIOGENESIS POLYMORPHISMS IN HCC PATIENTS TREATEDWITH SORAFENIB. INNOVATE STUDY 867
Utility of neutrophil-to-lymphocyte ratio to identify long-term survivors among HCC patients treated with sorafenib 867
Clinical and circulating biomarkers of survival and recurrence after radiofrequency ablation in patients with hepatocellular carcinoma 857
CDX-2 expression correlates with clinical outcomes in MSI-H metastatic colorectal cancer patients receiving immune checkpoint inhibitors 845
Neoadjuvant chemo-radiotherapy response in patients affected by mismatch repair deficient (dMMR) locally advanced rectal cancer 844
Retrospective Comparative Analysis of KRAS G12C vs. Other KRAS Mutations in mCRC Patients Treated With First-Line Chemotherapy Doublet + Bevacizumab 833
Multidisciplinary clinical guidelines in proactive monitoring, early diagnosis, and effective management of trastuzumab deruxtecan (T-DXd)-induced interstitial lung disease (ILD) in breast cancer patients 812
Liquid Biopsy-Driven Cetuximab Rechallenge Strategy in Molecularly Selected Metastatic Colorectal Cancer Patients 802
The prognostic nutritional index predicts survival and response to first-line chemotherapy in advanced biliary cancer 795
Impact of Aspirin on clinical outcome in advanced HCC patients receiving sorafenib and regorafenib 791
The outcome to axitinib or everolimus after sunitinib in metastatic renal cell carcinoma 786
Balance between the stem cell marker CD44 and CDX2 expression in colorectal cancer 785
Introducing immunotherapy for advanced hepatocellular carcinoma patients: Too early or too fast? 772
A Multidisciplinary Approach to Patients with Psoriasis and a History of Malignancies or On-Treatment for Solid Tumors: A Narrative Literature Review 760
Ramucirumab for the treatment of gastric cancers, colorectal adenocarcinomas, and other gastrointestinal malignancies 749
Totale 163.571
Salva come PNG Salva come JPEG
Categoria #
all - tutte 372.164
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 372.164
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202037.113 0 0 0 0 15.269 10.901 5.751 1.529 873 731 799 1.260
2020/202156.110 1.658 2.112 2.076 15.778 10.994 6.963 3.642 3.554 1.399 3.262 2.661 2.011
2021/202217.497 1.352 1.105 469 843 911 960 717 3.198 1.945 1.597 2.150 2.250
2022/202328.830 3.008 3.934 3.119 2.545 2.382 2.998 1.411 2.068 2.109 1.809 2.167 1.280
2023/202433.163 1.257 1.347 1.666 2.049 2.733 4.826 4.990 4.292 1.998 1.978 2.930 3.097
2024/202545.892 13.446 14.667 7.487 7.710 2.582 0 0 0 0 0 0 0
Totale 257.321